Dompé U.S. Agrees to $32 Million Settlement Over Alleged Medicare Co-Pay Kickbacks
Report date: (original source date). Article publication date: .
Report an error or privacy concernSummary
Dompé U.S. agreed to pay $32 million to resolve allegations that, between 2018 and 2021, it funded two patient assistance foundations that paid Medicare beneficiaries’ Oxervate co-pays, allegedly inducing purchases in violation of the Anti-Kickback Statute and False Claims Act. The DOJ said Dompé made contributions and obtained foundation and specialty-pharmacy patient assistance data.
Dompé farmaceutici self-disclosed the conduct, and Dompé farmaceutici and Dompé U.S. cooperated with the government. The settlement resolves the allegations; the source does not report criminal charges, a plea or a conviction, and says the companies received credit for self-disclosure, cooperation and remediation.
The case highlights risks where charitable patient-assistance programmes, third-party foundations and pharmacy hubs interact with product demand and patient data. Effective controls should scrutinise funding, programme design, information flows and independence of intermediaries.
